Addex Therapeutics Ltd. (ADXN)
| Market Cap | 41.88M |
| Revenue (ttm) | 4.72M |
| Net Income (ttm) | -14.19M |
| Shares Out | 5.88M |
| EPS (ttm) | -2.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 640 |
| Open | 7.67 |
| Previous Close | 7.32 |
| Day's Range | 7.00 - 7.12 |
| 52-Week Range | 7.50 - 35.00 |
| Beta | 1.41 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2021 |
About ADXN
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and col...
Financial Performance
In 2020, ADXN's revenue was 3.61 million, an increase of 30.77% compared to the previous year's 2.76 million. Losses were -12.86 million, -13.00% less than in 2019.
Financial numbers in millions CHFFinancial StatementsNews
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of 0.00% and 96.43%, respectively, for the quarter ended September 2021.
Addex Therapeutics Ltd. Sponsored ADR (ADXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Addex Therapeutics Ltd. Sponsored ADR (ADXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Addex Therapeutics, CMTA Join Forces To Develop Potential Treatment For Rare Neurological Disorder
The Charcot–Marie–Tooth Association (CMTA), a philanthropic funder of CMT research worldwide, and Addex Therapeutics Ltd (NASDAQ: ADXN) have collaborated to investigate a potential therapy for CMT type ...
New Strong Sell Stocks for August 20th
ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Tops Revenue Estimates
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -18.46% and 352.31%, respectively, for the quarter ended June 2021.
Addex Therapeutics (ADXN) Sees Hammer Chart Pattern: Time to Buy?
Addex Therapeutics (ADXN) has been struggling lately, but the selling pressure may be coming to an end soon.
Addex Reports Q1 2021 Financial Results and Provides Corporate Update
Ge neva, Switzerland, May 5 , 20 2 1 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, tod...
Enamine Extend Collaboration With Prominent Swiss Biotech
KYIV, Ukraine--(BUSINESS WIRE)--Enamine Ltd. a provider of drug discovery services empowered with the world's largest collections of building blocks, fragments and screening compounds announced today th...
Why Addex, Genetic Technologies And Obalon Are Moving Today
Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and sex alone...
Epilepsy Drug News: Why Addex Therapeutics (ADXN) Stock Is Soaring Today
Addex Therapeutics (ADXN) stock is soaring higher on Thursday after announcing news concerning a clinical trial for its epilepsy drug. The post Epilepsy Drug News: Why Addex Therapeutics (ADXN) Stock Is...
Addex Announces Pricing of $10.0 Million Global Offering
Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...